January 24, 2012—The Health Resources and Services Administration (HRSA) has set May as its target for issuing its long-awaited final rule to implement health care reform’s prohibition on 340B discounts for orphan drugs purchased by hospitals that became eligible for 340B under reform.
The projected timeframe for publication was included in the Department of Health and Human Services’ (HHS) latest semiannual regulatory agenda, dated fall 2011 and issued on Jan. 20. The twice-a-year report gives details about the most important regulatory actions that HHS expects to take in the next six months.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)